x
Elara Pharmaceuticals Ltd - Logo
[contact-form-7 404 "Not Found"]

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • 666-888-0000
  • info@elarapharma.com
Elara Pharmaceuticals Ltd - Logo
  • info@elarapharma.com
  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News
    • In The News
    • Publications
  • Careers
Logo

Contact Info

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • +44 20 8040 0302
  • info@elarapharma.com

Tag: recent post

Alzheimer's

Sep2018

Artificial Intelligence enables first biomarker driven precision medicine therapy against Alzheimer

Elara Pharmaceuticals Ltd helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase 2a clinical trial. Tersan’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73. Professor Harald Hampel, M.D., Ph.D., presenting results at the AAIC […]

Read More
Cancer

Sep2018

Recombio and Elara Pharmaceuticals Ltd Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy

Tersan has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Elara Pharmaceuticals Ltd (Paris, France and […]

Read More
Alzheimer's

Aug2018

Applying the cancer playbook to find treatment for Alzheimer’s disease

Applying the cancer playbook to find treatment for Alzheimer’s disease: see how Tersan’s KEM Artificial Intelligence platform is helping Anavex Life Sciences develop the first targeted therapy against Alzheimer’s disease.   “NEW YORK – July 25, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics […]

Read More

Posts navigation

1 2

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Elara Pharmaceuticals Ltd, The AI DRUG Development Company

  • The Barn Holly Berry House Rough Park,
    Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ
  • Call Us: +44 20 8040 0302
  • info@elarapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Elara Pharmaceuticals Ltd © 2024 All Rights Reserved